Myriad Genetics Inc. on Monday said its drug Flurizan failed to effect a significant improvement in patients with mild to moderate Alzheimer's disease, though some benefit was seen in certain patients with mild forms of the disease.
The Salt Lake City-based company said that while the drug, Flurizan, did not reach the main goal of a mid-stage, or Phase II clinical trial, enough positive trends were seen in patients with mild &to=http:// english.pravda.ru/mailbox/22/101/399/14257_Bushism.html ' target=_blank>Alzheimer's disease to warrant continuation of a Phase III, or late-stage trial.
The main goals of the trial included showing statistically significant improvements in the ability to carry out the activities of daily living such as eating and dressing and an slowing in the rate of cognitive decline.
Peruvian judges accused world elites of Covid crisis conspiracy. Although this is nonsense from a legal point of view, circumstantial evidence is evident